COMPASS Pathways (NASDAQ:CMPS) Posts Quarterly Earnings Results, Misses Expectations By $0.01 EPS

COMPASS Pathways (NASDAQ:CMPS) released its earnings results on Thursday. The company reported ($0.63) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.62) by ($0.01), Zacks reports.

COMPASS Pathways Price Performance

Shares of CMPS stock traded up $0.03 during trading hours on Friday, reaching $3.95. 475,183 shares of the company were exchanged, compared to its average volume of 1,251,092. The company has a debt-to-equity ratio of 0.15, a current ratio of 8.91 and a quick ratio of 8.91. The company has a market cap of $270.47 million, a price-to-earnings ratio of -1.79 and a beta of 2.28. The stock’s fifty day moving average is $4.06 and its two-hundred day moving average is $5.28. COMPASS Pathways has a fifty-two week low of $3.16 and a fifty-two week high of $12.57.

Wall Street Analysts Forecast Growth

A number of research firms have recently issued reports on CMPS. Canaccord Genuity Group lowered their price objective on COMPASS Pathways from $23.00 to $15.00 and set a “buy” rating on the stock in a research report on Friday. HC Wainwright lowered their price target on shares of COMPASS Pathways from $60.00 to $45.00 and set a “buy” rating on the stock in a report on Thursday, February 13th. Royal Bank of Canada restated an “outperform” rating and issued a $18.00 price objective on shares of COMPASS Pathways in a research note on Wednesday, January 15th. Maxim Group decreased their target price on shares of COMPASS Pathways from $22.00 to $12.00 and set a “buy” rating on the stock in a research report on Friday, November 1st. Finally, Stifel Nicolaus began coverage on shares of COMPASS Pathways in a research report on Thursday. They issued a “buy” rating and a $11.00 price target for the company. Seven investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company presently has an average rating of “Buy” and a consensus target price of $21.83.

COMPASS Pathways Company Profile

COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa.